Ustekinumab - search results

European Union - English - EMA (European Medicines Agency)

stelara

janssen-cilag international nv - ustekinumab - psoriasis; arthritis, psoriatic; crohn disease; colitis, ulcerative - immunosuppressants - crohn’s diseasestelara is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tnfα antagonist or have medical contraindications to such therapies.ulcerative colitisstelara is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.plaque psoriasisstelara is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen ultraviolet a.paediatric plaque psoriasisstelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.psoriatic arthritisstelara, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying antirheumatic drug (dmard) therapy has been inadequate.

New Zealand - English - Medsafe (Medicines Safety Authority)

stelara

janssen-cilag (new zealand) ltd - ustekinumab 45mg; - solution for injection - 45 mg - active: ustekinumab 45mg excipient: histidine as hydrochloride polysorbate 80 sucrose water for injection - stelara is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

stelara

janssen-cilag (new zealand) ltd - ustekinumab 90mg; - solution for injection - 90 mg - active: ustekinumab 90mg excipient: histidine as histidine hydrochloride polysorbate 80 sucrose water for injection - stelara is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.

New Zealand - English - Medsafe (Medicines Safety Authority)

stelara

janssen-cilag (new zealand) ltd - ustekinumab 130mg ((5.0 mg/ml)); - concentrate for infusion - 5 mg/ml - active: ustekinumab 130mg ((5.0 mg/ml)) excipient: edetic acid histidine histidine hydrochloride monohydrate methionine polysorbate 80 sucrose water for injection - crohn's disease: stelara is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a tnf-alpha antagonist or have medical contraindications to such therapies. other dose forms of stelara are approved for other indications (plaque psoriasis, and psoriatic arthritis). this dose form is not approved for these other indications. this dose form is only to be used for the induction dose associated with the treatment of crohn's disease.